1 week Ago By Defense World Staff
Bank of Montreal Can decreased its holdings in shares of BioAtla, Inc. ( NASDAQ:BCAB – Free Report ) by 87.7% in the 4th quarter, according to its most recent 13F filing with the SEC.
The fund owned 73,484 shares of the company’s stock after selling 522,252 shares during the period. Bank of Montreal Can owned approximately 0.15% of BioAtla worth $43,000 at the end of the most recent reporting period.
A number of other large investors also recently made changes to their positions in BCAB. Magnus Financial Group LLC acquired a new position in BioAtla during the fourth quarter valued at approximately $28,000. Norges Bank bought a new position in shares of BioAtla during the fourth quarter worth $230,000.
Finally, Highbridge Capital Management LLC acquired a new position in shares of BioAtla in the 4th quarter valued at $1,484,000. Institutional investors and hedge funds own 77.23% of the company’s stock.
Analysts Set New Price Targets Separately, HC Wainwright reaffirmed a “neutral” rating on shares of BioAtla in a research note on Monday, March 31st. BioAtla Price Performance NASDAQ:BCAB opened at $0.44 on Friday.
The business’s 50-day simple moving average is $0.34 and its 200-day simple moving average is $0.90.
BioAtla, Inc. has a fifty-two week low of $0.24 and a fifty-two week high of $3.
53. The stock has a market capitalization of $25.73 million, a PE ratio of -0.
26 and a beta of 1.08. BioAtla ( NASDAQ:BCAB – Get Free Report ) last announced its quarterly earnings results on Thursday, March 27th.
The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.
08. On average, research analysts expect that BioAtla, Inc. will post -1.
46 earnings per share for the current year. About BioAtla ( Free Report ) BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.
Recommended Stories Five stocks we like better than BioAtla 3 Dividend Kings To Consider Markets Think Robinhood Earnings Could Send the Stock Up What does consumer price index measure? Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? How to Use Stock Screeners to Find Stocks AT&T: Subscriber Growth & Buybacks Signal Bullish Turnaround Want to see what other hedge funds are holding BCAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioAtla, Inc. ( NASDAQ:BCAB – Free Report ).
Receive News & Ratings for BioAtla Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAtla and related companies with MarketBeat.com's FREE daily email newsletter ..
